Hopeful Therapies

Here to support your little one AND you

Uncategorized

Autism and Learning Disorders: How We Evaluate the Evidence at Hopeful Therapies

by

Leer este artículo en español

Series: The Whole Child · Pillar page

Our families navigate an information space full of contradictory promises. This page explains how we think about the relationship between autism, learning, and physical health; what has solid support and what doesn’t; and why we believe saying “we don’t know” when that’s the truth is part of responsible clinical service.

Published by the Hopeful Therapies clinical team · Updated: August 2026

Our position, in five statements

1. Autism is not a disease to be cured. It is a form of neurological development. Our job is not to make an autistic child appear non-autistic: it is to expand their communication skills, their independence, and their capacity to participate in the life they and their family want, and to reduce suffering where it exists. The difference between those two goals defines the ethical quality of an ABA program.

2. The best-supported interventions for skill development are behavioral and developmental. Applied behavior analysis, naturalistic developmental behavioral interventions, speech-language pathology, occupational therapy, and structured educational support. No biomedical intervention has yet shown comparable effects on communication, learning, and independence.

3. Many autistic children also have co-occurring medical conditions that deserve treatment in their own right. Chronic constipation, reflux, sleep disorders, epilepsy, anxiety, food selectivity with nutritional consequences. Treating those is not treating autism: it is attending to the child’s health. And when they go untreated, they reduce availability to learn and increase distress.

4. Complementary and integrative medicine in autism does not, as of today, have high-quality evidence. This is not our opinion. It is the conclusion of the broadest review conducted to date, published in Nature Human Behaviour in December 2025, which assessed 248 meta-analyses across 19 interventions and more than 10,000 participants [1]. A parallel systematic review of 115 randomized trials concluded that clinical use is fully evidence-based only for melatonin in sleep disturbance [2].

5. Our scope of practice is a boundary, not a limitation. We do not prescribe, do not recommend supplements or diets, and do not interpret lab results. What we do — and few on a child’s team can — is measure rigorously. When a family and their physician decide to try something, we can turn that trial into real information rather than an impression.

Why we publish this. A good deal of popular autism content is produced by whoever sells the recommended product. We sell ABA services, and we say so openly. We hold no commercial relationship with any supplement manufacturer, laboratory, or testing provider, and we receive no compensation for referrals. When this series says something lacks sufficient evidence, there is no alternative product of ours waiting at the end of the article.

The full series

The Whole Child: Autism, Learning, and Health

  1. Beyond Behavior: How ABA Coordinates With Medicine When Co-Occurring Biological Conditions Are Present
    The overall frame. What biologically-based motivating operations are, the actual state of the evidence in 2026, and how coordination with the pediatrician works.
  2. Gut and Behavior: Why Digestive Distress Shows Up in Session Data
    The 2010 pediatric consensus, biopsy studies on digestive enzymes, what microbiome research does and doesn’t show, and what data to bring to the gastroenterologist.
  3. Supplements and Autism: How to Read the Evidence Before Spending Money and Hope
    The five compounds that run through the whole conversation, their actual trials and limits; what the FDA decided about leucovorin in March 2026; and five questions to ask before buying.

A resource we recommend that sells nothing

The research team behind the Nature Human Behaviour review also built a public, searchable database where any family or professional can review, intervention by intervention, what evidence exists and at what quality: ebiact-database.com [1].

If someone recommends an intervention for your child, that’s the first place to check it. It’s independent, free, and has no store.

How we work with the rest of your child’s team

The best care we’ve seen happens when the pediatrician, the ABA team, the school, the speech-language pathologist, and the family share information rather than operating in parallel. In practice, that means concrete things:

We document and communicate behavioral patterns that may have a medical origin, with data and dates, and we recommend medical evaluation before intensifying behavioral procedures when those patterns are present. We build sleep, bowel movements, illness, and medication changes into routine data collection, because without those variables a functional analysis loses explanatory power. With family authorization, we share data summaries with the treating physician and the school. And when a family decides, together with their physician, to try a biomedical intervention, we offer structured measurement with a baseline so the result is evaluable.

Note for referring professionals

If you are a pediatrician, developmental neurologist, pediatric gastroenterologist, or speech-language pathologist working with a patient in our program, you can request from us — with family authorization — a behavioral data summary oriented to your clinical question: temporal distribution of problem behavior, correlation with meals and sleep, episode latency, comparative rates by time of day, and a quantified baseline prior to the start of any intervention you order. We prepare that material at no additional cost to families in active service. Our role is to contribute behavioral measurement, not medical interpretation.

Questions about your child’s program? Our clinical team can meet with you to review your data, discuss goals, and explain how we coordinate with your pediatrician. Call (813) 655-8159 or write to contact@hopefultherapies.com. We serve families in Brandon, Lakeland and Winter Haven, Florida.

About this series. This series discusses and responds to a set of articles on autism and functional medicine by Jill Carnahan, MD, published by the Foundation for Alternative and Integrative Medicine and collected in its Autism and Learning Disorders section. All text in this series is original to Hopeful Therapies. We verified the primary sources cited in the original articles and, where our reading of the evidence differs, we say so explicitly with the corresponding source. We do not reproduce the originals’ product recommendations or dosing protocols. We thank FAIM for publishing material that prompts this conversation, and we encourage interested families to read the original articles alongside this series and form their own view.

References

  1. Gosling CJ, Boisseleau L, Solmi M, et al. Complementary, alternative and integrative medicine for autism: an umbrella review and online platform. Nat Hum Behav. 2025;9(12):2610-2619. nature.com/articles/s41562-025-02256-9 · Platform: ebiact-database.com
  2. Persico AM, Asta L, Chehbani F, et al. The pediatric psychopharmacology of autism spectrum disorder — Part II: The future. Prog Neuropsychopharmacol Biol Psychiatry. 2025;136:111176. sciencedirect.com
  3. Buie T, Campbell DB, Fuchs GJ III, et al. Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics. 2010;125(Suppl 1):S1-S18. doi:10.1542/peds.2009-1878C
  4. Behavior Analyst Certification Board. Ethics Code for Behavior Analysts. bacb.com/ethics-information/ethics-codes

Important notice. Hopeful Therapies provides applied behavior analysis (ABA) services. We are not a medical provider and do not diagnose or treat medical conditions, nor do we prescribe or recommend diets, supplements, or medications. This content is educational and does not constitute medical advice or substitute for the relationship with your pediatrician or other qualified health professional. Do not start, stop, or change any treatment, diet, or supplement based on this post. Our services are delivered in accordance with the BACB Ethics Code for Behavior Analysts and applicable Florida Agency for Health Care Administration (AHCA) requirements. We have no commercial relationship with any supplement manufacturer, laboratory, or testing provider mentioned or linked in this series, and we receive no compensation for referrals. No identifiable client information is used in our educational content; examples are illustrative and composite.

Supplements and Autism: How to Read the Evidence Before Spending Money and Hope

by

Leer este artículo en español

Series: The Whole Child · Part 3 of 4

Folinic acid, N-acetylcysteine, L-carnitine, coenzyme Q10, sulforaphane. These five compounds run through the entire biomedical conversation about autism. This post explains what the trials actually show, what the FDA decided about leucovorin in 2026, and how to evaluate any intervention without relying on subjective impression.

Published by the Hopeful Therapies clinical team · 11 min read

Read this first. Hopeful Therapies is an applied behavior analysis provider. We do not prescribe, recommend, or sell supplements, and we deliberately omit dosages on this page. We wrote this because our families ask about these compounds almost every week, and they deserve an honest read of the evidence rather than promotional material. Every decision about supplementation for a child belongs to their physician.

The question behind the question

When a parent asks us about folinic acid, they are almost never asking about biochemistry. They are asking: am I leaving something untried?

That question deserves respect and a direct answer. Ours is that there is an important difference between “there is a trial with interesting results” and “this works,” and that the supplement industry makes money by blurring that difference. Learning to tell them apart is the most useful skill a family can develop in this field — more useful than any product list.

The frame: two large reviews, two compatible conclusions

In December 2025, Nature Human Behaviour published an umbrella review from Corentin Gosling’s team assessing 248 meta-analyses, roughly 200 clinical trials, and more than 10,000 participants across 19 complementary, alternative, and integrative medicine interventions in autism. Conclusion: there is no high-quality evidence supporting the efficacy of any of them for core or associated autism symptoms. Several showed promising signals, resting on very low-quality evidence [1]. They also published an open, searchable database: ebiact-database.com. If you save only one link from this series, save that one.

Antonio Persico and colleagues’ systematic review covered 115 randomized controlled trials across 133 compounds and reached a somewhat different but compatible formulation: clinical use is fully evidence-based only for melatonin, and for six additional compounds clinical use may be acceptable with caution, though more research is necessary [2]. Those six are folinic acid, N-acetylcysteine, L-carnitine, coenzyme Q10, sulforaphane, and metformin (the last a prescription medication we don’t discuss here).

Editorial accuracy note. This review is frequently cited as though it declared those six compounds “promising and safe” for clinical use. The authors’ phrasing is more cautious, and the difference matters: the only compound they treat as fully evidence-based is melatonin. We flag it because a family reading “promising and safe” makes a different decision than one reading “more research is necessary.”

The five compounds, with their actual evidence

Compound Best available evidence Key limitations
Folinic acid (leucovorin) Frye et al., Molecular Psychiatry 2018: double-blind RCT, 48 children, 12 weeks; improvement in verbal communication versus placebo [3]. Panda et al., European Journal of Pediatrics 2024: RCT, 80 children, 24 weeks [4]. The 2018 trial’s own authors describe the findings as preliminary until assessed in larger, longer multicenter studies. It is a prescription medication.
N-acetylcysteine (NAC) Hardan et al., Biological Psychiatry 2012: pilot RCT, reduced irritability [5]. Wink et al., Molecular Autism 2016: raised blood glutathione but showed no significant effect on the primary social impairment outcome [6]. Reported effects are on irritability, not core traits. Small-sample pilot trials. Mixed results.
L-carnitine Geier et al., Medical Science Monitor 2011: RCT, 30 children, 3 months [7]. Mechanistic basis: Rossignol & Frye review of mitochondrial dysfunction [8]. Very small sample. A single principal randomized trial. Plausibly applicable only in children with documented mitochondrial weakness.
Coenzyme Q10 Mousavinejad et al., Psychiatry Research 2018: 90 children, improvements in oxidative stress markers and in sleep and GI symptoms [9]. Positive outcomes were biochemical markers and associated symptoms, not core autism traits.
Sulforaphane Singh et al., PNAS 2014: RCT in 44 young men (ages 13-27); 34% reduction in Aberrant Behavior Checklist and 17% in Social Responsiveness Scale [10]. The replication trial in children aged 3-12 (Zimmerman et al., Molecular Autism 2021) did not reach significance on its primary outcome [11]. This is exactly the pattern that demands caution.

The last row is worth pausing on, because it teaches you how to read the rest of the table. Sulforaphane produced a striking result in 2014 in adolescents and young adults, and when the same research group tried to replicate it in younger children in 2021, the primary outcome was not significant. That is the normal cycle of science and the reason a single positive trial isn’t enough. When a product is marketed citing only the 2014 study, the omission is not accidental.

The leucovorin case: what actually happened

This is the part of this post we consider most important, because a great deal of imprecise information circulates and because it affects real families’ decisions.

The scientific starting point is solid. There is a condition called cerebral folate deficiency, in which folate does not adequately reach the brain even when blood levels appear normal. One cause is autoantibodies against the folate receptor alpha, reviewed by Daniel Rossignol and Richard Frye in Journal of Personalized Medicine in 2021 [12]. Folinic acid can bypass that blocked transport, and the Frye 2018 and Panda 2024 trials tested precisely that [3][4].

What happened next on the regulatory side has often been told badly. The verifiable sequence is this:

  • In September 2025 the FDA asked GSK to refile an application for leucovorin for cerebral folate deficiency — an unusual move — and public communications linked the condition to “developmental delays with autistic features.”
  • In March 2026 the FDA approved leucovorin (Wellcovorin) exclusively for cerebral folate deficiency with a confirmed FOLR1 gene variant, an ultra-rare genetic form that, per an agency official, affects fewer than 1 in a million people. The approval was not for autism.
  • GSK subsequently withdrew its application. This does not affect the availability of generic leucovorin.

Editorial accuracy note. We have seen this process described as though the FDA recognized leucovorin as an autism treatment, or as though such approval were the natural next step. It is not. The approval covered a genetic condition affecting fewer than 1 in 1,000,000 people, and the agency was explicit that it was not approving an autism indication. Folate receptor autoantibodies — which are indeed common in autism per the 2021 review — are a distinct entity from the FOLR1 variant the approval covers. Conflating them leads a family to believe an approved treatment exists where none does.

None of this means the research line is invalid. It means that as of August 2026, folinic acid for autism remains an off-label use supported by two randomized trials whose own authors describe the results as preliminary. It’s a legitimate conversation with a physician. It is not an established treatment.

Methylation and glutathione

The biochemical basis is real. Jill James and colleagues at the University of Arkansas documented in American Journal of Clinical Nutrition in 2004 that autistic children, as a group, show measurable abnormalities in the methionine-homocysteine-glutathione cycle: lower S-adenosylmethionine, lower cysteine, lower reduced glutathione, and a higher ratio of oxidized to reduced glutathione [13]. In 2009 the same group published a study in which methylcobalamin and folinic acid over three months corrected those biochemical markers [14].

That second study is the one to read carefully. It showed the biochemistry can be normalized. Showing that normalizing the biochemistry improves the child’s life is a different question, requiring randomized trials with functional outcomes, blinding, and control groups. Improving a lab marker is an intermediate outcome, not a clinical one. Medicine has a long history of interventions that corrected the marker without benefiting the patient.

We add a safety consideration that gets little mention: methylation support is not innocuous. Clinical practice reports irritability, hyperactivity, or sleep disruption with certain doses or forms of methyl donors with some regularity. A compound that can worsen a child’s behavior requires medical supervision, not self-experimentation.

What these reviews say does NOT work

Equally useful, and published less. The Persico review explicitly notes that current evidence does not support, for core autism traits, hyperbaric oxygen therapy, high-dose intravenous immunoglobulin outside specific immune indications, secretin, or the older megavitamin protocols using high-dose pyridoxine and magnesium [2].

We mention it because these are expensive interventions, some invasive, and well-meaning families continue to invest finite resources in them.

Clinical note for BCBAs and RBTs

Our usefulness here is not in opining on the compound. It’s in measurement design, which is literally our specialty and which almost no one else on the child’s team can contribute.

Offer structured measurement, not opinion. When a family reports that their physician is starting a biomedical intervention, the appropriate response is neither to endorse nor discourage it, but to offer what we know how to do: establish baseline, operationally define the outcomes the family says matter to them, and measure with the same procedure before, during, and after.

Minimum defensible design. Baseline of at least 2-3 weeks before onset; operationally defined outcomes prioritized by the family; continuous measurement using the same procedure; validated scales administered by the same informant at the same intervals; and explicit logging of concurrent changes in the ABA program, medication, school setting, or sleep. Without that last item, the design isn’t interpretable.

Caution on causal attribution. An AB design in a single case does not permit causal attribution. Maturation, regression to the mean, caregiver expectancy, and concurrent therapy effects remain unruled-out alternatives. Communicate this to the family before starting, not after seeing the data. Where clinical and ethical context permits, a withdrawal or multielement design contributes far more — but that is the prescribing physician’s decision, not ours.

Document adverse behavioral reactions. Increased irritability, sleep disruption, or increased problem behavior following the start of a supplement is clinically relevant information the physician needs. Report it with data and dates, without interpreting mechanism.

Role boundary. We do not recommend compounds or doses, do not interpret lab results, do not validate biomedical protocols, and do not refer to providers in whom we hold any financial interest. BACB standards 2.01, 2.03, 1.11, and 1.13.

For families: five questions before you buy

We find these five questions more useful than any product list:

1. Is there more than one placebo-controlled randomized trial, and did the result replicate? A single positive trial is a starting point. A failed replication attempt — like sulforaphane’s in younger children — is essential information that advertising omits.

2. What exactly was measured? Many positive results are about irritability, sleep, or lab markers, not communication, learning, or independence. That may still be worthwhile, but it’s different from what’s usually promised.

3. Who measured? If the outcome was reported by the caregiver who knew their child was receiving active treatment, the result incorporates expectancy. That’s not fraud; it’s a known design limitation.

4. Who benefits if I buy this? If the article that informed you links to the store selling the product, that doesn’t invalidate the science cited, but it should change how you weight the recommendation. Check it against the EBIACT database, which sells nothing.

5. How will I know if it worked? If you can’t answer this before starting, then six months from now you likely won’t know whether the change you’re seeing came from the supplement, the ABA program, the new school year, or your child’s normal development. Here we can help, and that’s what we offer.

One last point, said with care. None of these interventions has shown effects comparable to what your child gets from well-implemented behavioral and developmental intervention, delivered consistently, by a team that knows them. That’s the best-supported work, and also the least marketed — because no one has a product to sell.

Questions about your child’s program? Our clinical team can meet with you to review your data, discuss goals, and explain how we coordinate with your pediatrician. Call (813) 655-8159 or write to contact@hopefultherapies.com. We serve families in Brandon, Lakeland and Winter Haven, Florida.

About this series. This post discusses and responds to “The Most Evidence-Based Biochemical Therapies for Autism: Folinic Acid, NAC, Methylation Support, and Beyond” by Jill Carnahan, MD, published by the Foundation for Alternative and Integrative Medicine. The text on this page is original to Hopeful Therapies. We verified the primary sources the author cites and, where our reading differs, we say so with the corresponding source. The original article includes pediatric dosages and links to supplement products marketed by the author; we reproduce none of them, because prescribing falls outside our scope of practice and because we hold no commercial relationships with supplement vendors.

References

  1. Gosling CJ, Boisseleau L, Solmi M, et al. Complementary, alternative and integrative medicine for autism: an umbrella review and online platform. Nat Hum Behav. 2025;9(12):2610-2619. nature.com/articles/s41562-025-02256-9
  2. Persico AM, Asta L, Chehbani F, et al. The pediatric psychopharmacology of autism spectrum disorder — Part II: The future. Prog Neuropsychopharmacol Biol Psychiatry. 2025;136:111176. sciencedirect.com
  3. Frye RE, Slattery J, Delhey L, et al. Folinic acid improves verbal communication in children with autism and language impairment. Mol Psychiatry. 2018;23(2):247-256. nature.com/articles/mp2016168
  4. Panda PK, Sharawat IK, Saha S, et al. Efficacy of oral folinic acid supplementation in children with autism spectrum disorder. Eur J Pediatr. 2024;183(11):4827-4835. doi:10.1007/s00431-024-05762-6
  5. Hardan AY, Fung LK, Libove RA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry. 2012;71(11):956-961. doi:10.1016/j.biopsych.2012.01.014
  6. Wink LK, Adams R, Wang Z, et al. A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder. Mol Autism. 2016;7:26. doi:10.1186/s13229-016-0088-6
  7. Geier DA, Kern JK, Davis G, et al. A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders. Med Sci Monit. 2011;17(6):PI15-PI23. doi:10.12659/msm.881792
  8. Rossignol DA, Frye RE. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry. 2012;17(3):290-314. doi:10.1038/mp.2010.136
  9. Mousavinejad E, Ghaffari MA, Riahi F, et al. Coenzyme Q10 supplementation reduces oxidative stress in children with autism spectrum disorders. Psychiatry Res. 2018;265:62-69. doi:10.1016/j.psychres.2018.03.061
  10. Singh K, Connors SL, Macklin EA, et al. Sulforaphane treatment of autism spectrum disorder (ASD). Proc Natl Acad Sci U S A. 2014;111(43):15550-15555. doi:10.1073/pnas.1416940111
  11. Zimmerman AW, Singh K, Connors SL, et al. Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder. Mol Autism. 2021;12(1):38. doi:10.1186/s13229-021-00447-5
  12. Rossignol DA, Frye RE. Cerebral folate deficiency, folate receptor alpha autoantibodies and leucovorin (folinic acid) treatment in autism spectrum disorders. J Pers Med. 2021;11(11):1141. PubMed 34834493
  13. James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr. 2004;80(6):1611-1617. doi:10.1093/ajcn/80.6.1611
  14. James SJ, Melnyk S, Fuchs G, et al. Efficacy of methylcobalamin and folinic acid treatment on glutathione redox status in children with autism. Am J Clin Nutr. 2009;89(1):425-430. doi:10.3945/ajcn.2008.26615
  15. On the FDA’s leucovorin decision (March 2026): BioPharma Dive; Fierce Pharma; BioSpace (GSK’s subsequent withdrawal of the application).

Important notice. Hopeful Therapies provides applied behavior analysis (ABA) services. We are not a medical provider and do not diagnose or treat medical conditions, nor do we prescribe or recommend diets, supplements, or medications. Dosages from the cited trials have been deliberately omitted from this page. This content is educational and does not constitute medical advice or substitute for the relationship with your pediatrician or other qualified health professional. Do not start, stop, or change any treatment or supplement based on this post. Several compounds mentioned can produce adverse effects, including behavioral changes, and can interact with medications; their use in minors requires medical supervision. Our services are delivered in accordance with the BACB Ethics Code for Behavior Analysts and applicable Florida Agency for Health Care Administration (AHCA) requirements. We have no commercial relationship with any supplement manufacturer, laboratory, or testing provider mentioned or linked in this series, and we receive no compensation for referrals.

Gut and Behavior: Why Digestive Distress Shows Up in Session Data

by

Leer este artículo en español

Series: The Whole Child · Part 2 of 4

If a child can’t say “my stomach hurts,” they will say it another way. In our records it appears as task refusal, self-injury directed at the abdomen, or an entire afternoon out of range. This post reviews what the research shows about gastrointestinal function in autism, and defines precisely where our role ends and the pediatrician’s begins.

Published by the Hopeful Therapies clinical team · 9 min read

One fact changes the conversation with families more than any other, in our experience: chronic constipation and abdominal pain are not treated with less urgency in autistic children because they are less common, but because they are harder to report. When a child with typical language says their stomach hurts, they go to the pediatrician. When a minimally verbal child expresses it by hitting their abdomen or refusing the work table, too often what they get is a more intensive behavior plan.

That mistake has a technical name in our field. It’s a misidentification of behavioral function. And it has a real cost to the child.

The starting point: the 2010 consensus, still current

In 2010, Pediatrics published a consensus report from a panel of pediatric gastroenterologists, neurologists, immunologists, and developmental specialists led by Timothy Buie [1]. Its core conclusions — written by physicians, not by advocates of alternative therapies — were three: GI disorders are common in autistic individuals; they should be evaluated and treated to the same standard as in any other patient; and in nonverbal or minimally verbal children behavioral problems may be the only outward manifestation of underlying GI distress.

Two years later, Daniel Coury and colleagues published in the same journal a call for a dedicated research agenda on GI conditions in autism, citing the consistency and severity of the problem [2]. And in 2018, Calliope Holingue and colleagues’ systematic review in Autism Research estimated that prevalence of at least one GI symptom in autistic children falls between 23% and 70% depending on study design [3].

That range deserves comment, because it is the kind of figure that gets cited badly. The reason it spans 23% to 70% is not that studies contradict each other: it’s that defining and measuring “GI symptom” in a population with communication difficulties is methodologically hard, and studies using structured parent report find higher figures than those using medical records. The honest statement is that this is a common and probably underdiagnosed problem — not that it affects “7 in 10 autistic children.”

What microbiome studies have found

When the gut microbiomes of autistic children have been systematically compared to neurotypical children, some patterns have recurred. We summarize them with their confidence level, not as established fact.

Finding Primary source How to read it
Reduced Bifidobacterium; GI symptom severity correlated with autism severity Adams et al., BMC Gastroenterology 2011 (58 autistic children, 39 controls) [4] Correlation, not causation. Small sample. Consistent with other work.
Elevated Clostridium species Song, Liu & Finegold, Applied and Environmental Microbiology 2004 [5] Replicated by several groups. Clinical significance not yet established.
Elevated Desulfovibrio; lower microbial diversity Finegold et al., Anaerobe 2010 [6] Pyrosequencing study, small sample.
Altered bacterial genes for sulfur metabolism and oxidative stress detoxification Nirmalkar et al., International Journal of Molecular Sciences 2022 [7] Shotgun metagenomics. Interesting mechanistic finding; not a diagnostic test.

A caution about this body of literature as a whole. Microbiome research in autism consists largely of cross-sectional studies with small samples and inadequate dietary control — and the diet of a child with severe food selectivity is, by itself, a plausible explanation for an altered microbiome. The direction of causality, for most of these findings, is not established. We do not know whether a different microbiome contributes to symptoms, results from diet and medication use, or both.

Digestive enzyme insufficiency: the most concrete finding

Of everything above, the line of research with the most direct clinical implications is probably the least discussed. It comes from endoscopic biopsy studies, not questionnaires.

In 1999, Karoly Horvath and colleagues evaluated 90 autistic children undergoing endoscopy and found 49% had at least one deficient disaccharidase enzyme (lactase, maltase, sucrase, palatinase, or glucoamylase), and 20% had deficiencies in two or more; lactase deficiency was most common [8]. Brent Williams and colleagues confirmed and extended these findings in PLoS ONE in 2011, also documenting altered intestinal microbiota associated with the carbohydrate digestion impairment [9].

The largest study came from Massachusetts General Hospital and Harvard Medical School: Rafail Kushak, Timothy Buie, and colleagues evaluated intestinal biopsies from 199 autistic individuals aged 22 months to 28 years, finding lactase deficiency in 62%, sucrase deficiency in 16%, and maltase deficiency in 10% [10]. An important detail: the problem was as common in adults as in children, suggesting it isn’t a developmental phase that resolves on its own.

The implication is mechanically simple. If a child cannot digest the lactose in milk or the sucrose in fruit, those undigested sugars reach the intestine where they ferment, producing gas, distension, and pain. And pain, in a child who cannot report it, appears as behavior. This also explains why some families observe notable changes after removing a specific food: not because of any magic property of the food, but because the child couldn’t digest it.

What this means for a family. There is a concrete, established medical test — disaccharidase activity measurement on biopsy during endoscopy — that can identify this. It is not experimental and not from an alternative lab: it is part of the standard gastroenterology workup. The 2010 Buie consensus report specifically recommends endoscopic evaluation in autistic children with persistent GI symptoms [1]. If your child has distension, pain, or recurrent behavioral disturbance tied to meals, it is reasonable to ask your pediatrician whether a referral to pediatric gastroenterology is warranted.

Intestinal permeability: a real finding, an overloaded term

Laura de Magistris and colleagues published a 2010 study in Journal of Pediatric Gastroenterology and Nutrition comparing intestinal permeability across autistic children, their first-degree relatives, and healthy controls. They found elevated permeability in 36.7% of autistic children versus 4.8% of controls [11].

It’s a replicated and methodologically sound finding. At the same time, the popular term “leaky gut” has become a catch-all used to explain almost any symptom and to sell almost any product. Altered intestinal permeability is a measurable phenomenon; “leaky gut” as a universal explanatory diagnosis is not. Both are true and worth holding together.

Probiotics and microbiota transfer: where the evidence actually stands

Probiotics

We’re direct here because that’s what’s warranted. Persico and colleagues’ systematic review of 115 randomized controlled trials specifically examined the probiotic literature and concluded that available RCT evidence is insufficient to support probiotics as a treatment for core autism features [12]. The Gosling 2025 review reaches a compatible conclusion [13]. Trials have been small, using different strains and different protocols, with mixed results.

This is not the same as saying no child benefits. It means that today it cannot be claimed that they work for autism, and that any decision about probiotics for a child belongs to their pediatrician or gastroenterologist, weighing the specific digestive picture rather than the autism diagnosis.

Microbiota transfer therapy

This is the most striking finding in the field and also the most misrepresented.

In 2017, the team of Rosa Krajmalnik-Brown, James Adams, and Dae-Wook Kang at Arizona State University published an open-label, uncontrolled trial of Microbiota Transfer Therapy (MTT) in 18 autistic children with chronic GI symptoms. The protocol combined vancomycin, a bowel cleanse, a stomach acid suppressant, and fecal microbiota transplant from screened healthy donors, followed by maintenance dosing [14]. In 2019 the same team published a two-year follow-up in Scientific Reports on the same 18 children: a 58% reduction in the Gastrointestinal Symptom Rating Scale from baseline, and a 45% reduction in core autism symptoms by professional evaluator [15]. Microbiome changes persisted, with increases in bacterial diversity and in relative abundance of Bifidobacterium and Prevotella.

Editorial accuracy note. We have seen these figures cited as “59%” and “47%.” The figures published by Kang and colleagues in 2019 are 58% (GSRS) and 45% (core symptoms, professional evaluator) [15]. More important than the decimal: this was an open-label study of 18 participants with no placebo group. In a population where assessment depends partly on observation by non-blinded caregivers and evaluators, and across two years of natural development and concurrent therapies, improvement cannot confidently be attributed to the treatment. The authors themselves note the need for placebo-controlled trials. Those phase 2 trials are underway. Until they publish, this is a promising hypothesis, not a treatment. MTT is not clinically available for autism in the United States outside research protocols, and fecal transplant outside authorized trials carries infection risks documented by the FDA.

Early-childhood antibiotics

Several studies have documented higher oral antibiotic use in early childhood among children later diagnosed with autism, compared to controls — including the early medical history analysis by Rebecca Niehus and Catherine Lord [16]. This finding is real and merits investigation, and it is also a textbook example of why correlation isn’t enough: children who receive more antibiotics are children who have more infections and more medical visits, which in turn is associated with more opportunities for early detection. Whether this reflects causation, confounding by indication, or detection bias has been debated for years.

What is an established pediatric recommendation, independent of autism, is antibiotic stewardship: prescribing them when indicated and not for viral infections. That’s decided in the medical visit.

Clinical note for BCBAs and RBTs

Our contribution in this area is measurement, and it’s more valuable than usually recognized.

Indicators warranting communication to the family with a recommendation for medical evaluation: problem behavior with a consistent postprandial pattern; self-injury directed at the abdomen, abdominal pressure against objects, guarding postures; sudden refusal of previously accepted foods; cyclical behavioral disturbance with no identifiable environmental correlate in the functional analysis; regression of mastered skills; problem behavior unresponsive to a well-implemented plan with verified treatment integrity.

Data a pediatric gastroenterologist can use: bowel movement logs (frequency and consistency, Bristol scale if the family can apply it), correlation between problem behavior and time windows relative to meals, latency from intake to episode, and comparison of behavior rates in morning versus afternoon sessions. A one-page graph of that temporal correlation is more useful in the appointment than a narrative description.

Functional analysis integrity. When untreated medical distress operates as a motivating variable, functional analysis results can be unstable or inconsistent across conditions. If you observe that instability, consider a medical cause as an explanatory hypothesis before reformulating the plan a third time.

Role boundary. We do not suggest specific lab tests, do not interpret stool panel results, and do not recommend probiotics, enzymes, or elimination protocols. We describe behavior, provide data, recommend medical consultation, and document the referral in the record. This is what BACB standards 2.01, 2.03, and 3.06 require.

For families

If you suspect something digestive sits behind your child’s behavior, the shortest route doesn’t go through the internet. It goes through two weeks of simple logging — bowel movements, sleep, and what time the hard episodes happened — a copy of the behavioral data your ABA team is already collecting, and a pediatric appointment where you ask specifically whether a referral to pediatric gastroenterology is warranted.

Our team can prepare that data summary for you. You only have to ask.

Questions about your child’s program? Our clinical team can meet with you to review your data, discuss goals, and explain how we coordinate with your pediatrician. Call (813) 655-8159 or write to contact@hopefultherapies.com. We serve families in Brandon, Lakeland and Winter Haven, Florida.

About this series. This post discusses and responds to “The Gut-Brain Connection in Autism: Why Healing the Microbiome Can Transform Neurodevelopmental Health” by Jill Carnahan, MD, published by the Foundation for Alternative and Integrative Medicine. The text on this page is original to Hopeful Therapies. We verified the primary sources the author cites; where our reading of the evidence differs, we say so. The original article includes product recommendations and supplementation protocols that we do not reproduce here, because they fall outside an ABA provider’s scope of practice and because we have no commercial relationship with any manufacturer.

References

  1. Buie T, Campbell DB, Fuchs GJ III, et al. Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics. 2010;125(Suppl 1):S1-S18. doi:10.1542/peds.2009-1878C
  2. Coury DL, Ashwood P, Fasano A, et al. Gastrointestinal conditions in children with autism spectrum disorder: developing a research agenda. Pediatrics. 2012;130(Suppl 2):S160-S168. doi:10.1542/peds.2012-0900N
  3. Holingue C, Newill C, Lee LC, Pasricha PJ, Fallin MD. Gastrointestinal symptoms in autism spectrum disorder. Autism Res. 2018;11(1):24-36. doi:10.1002/aur.1854
  4. Adams JB, Johansen LJ, Powell LD, Quig D, Rubin RA. Gastrointestinal flora and gastrointestinal status in children with autism. BMC Gastroenterol. 2011;11:22. doi:10.1186/1471-230X-11-22
  5. Song Y, Liu C, Finegold SM. Real-time PCR quantitation of clostridia in feces of autistic children. Appl Environ Microbiol. 2004;70(11):6459-6465. doi:10.1128/AEM.70.11.6459-6465.2004
  6. Finegold SM, Dowd SE, Gontcharova V, et al. Pyrosequencing study of fecal microflora of autistic and control children. Anaerobe. 2010;16(4):444-453. doi:10.1016/j.anaerobe.2010.06.008
  7. Nirmalkar K, Qureshi F, Kang DW, Hahn J, Adams JB, Krajmalnik-Brown R. Shotgun metagenomics study suggests alteration in sulfur metabolism and oxidative stress in children with autism. Int J Mol Sci. 2022;23(21):13481. doi:10.3390/ijms232113481
  8. Horvath K, Papadimitriou JC, Rabsztyn A, Drachenberg C, Tildon JT. Gastrointestinal abnormalities in children with autistic disorder. J Pediatr. 1999;135(5):559-563. doi:10.1016/s0022-3476(99)70052-1
  9. Williams BL, Hornig M, Buie T, et al. Impaired carbohydrate digestion and transport and mucosal dysbiosis in the intestines of children with autism. PLoS One. 2011;6(9):e24585. doi:10.1371/journal.pone.0024585
  10. Kushak RI, Lauwers GY, Winter HS, Buie TM. Intestinal disaccharidase activity in patients with autism. Autism. 2011;15(3):285-294. doi:10.1177/1362361310369142
  11. de Magistris L, Familiari V, Pascotto A, et al. Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J Pediatr Gastroenterol Nutr. 2010;51(4):418-424. doi:10.1097/MPG.0b013e3181dcc4a5
  12. Persico AM, Asta L, Chehbani F, et al. The pediatric psychopharmacology of autism spectrum disorder — Part II: The future. Prog Neuropsychopharmacol Biol Psychiatry. 2025;136:111176. sciencedirect.com
  13. Gosling CJ, Boisseleau L, Solmi M, et al. Complementary, alternative and integrative medicine for autism: an umbrella review and online platform. Nat Hum Behav. 2025;9(12):2610-2619. nature.com/articles/s41562-025-02256-9
  14. Kang DW, Adams JB, Gregory AC, et al. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome. 2017;5(1):10. doi:10.1186/s40168-016-0225-7
  15. Kang DW, Adams JB, Coleman DM, et al. Long-term benefit of Microbiota Transfer Therapy on autism symptoms and gut microbiota. Sci Rep. 2019;9(1):5821. nature.com/articles/s41598-019-42183-0
  16. Niehus R, Lord C. Early medical history of children with autism spectrum disorders. J Dev Behav Pediatr. 2006;27(2 Suppl):S120-S127. doi:10.1097/00004703-200604002-00010

Important notice. Hopeful Therapies provides applied behavior analysis (ABA) services. We are not a medical provider and do not diagnose or treat medical conditions, nor do we prescribe diets, supplements, enzymes, probiotics, or medications. This content is educational and does not constitute medical advice or substitute for the relationship with your pediatrician or other qualified health professional. Do not start, stop, or change any treatment, diet, or supplement based on this post. Fecal microbiota transplant outside authorized research protocols carries documented risks and should not be attempted independently. Our services are delivered in accordance with the BACB Ethics Code for Behavior Analysts and applicable Florida Agency for Health Care Administration (AHCA) requirements. We have no commercial relationship with any supplement manufacturer, laboratory, or testing provider mentioned or linked in this series.

Beyond Behavior: How ABA Coordinates With Medicine When Co-Occurring Biological Conditions Are Present

by

Leer este artículo en español

Series: The Whole Child · Part 1 of 4

Autism is diagnosed behaviorally, but many autistic children also live with co-occurring medical conditions — GI pain, fragmented sleep, nutritional deficiencies — that reduce their availability to learn. Acknowledging this doesn’t change what we do as behavior analysts. It changes who we do it with.

Published by the Hopeful Therapies clinical team · 8 min read

Nearly every week we talk with a parent who brings the same concern. Their child is in the program, the team is taking data, there’s progress on some goals. And yet there are days when the child arrives and simply isn’t available. Irritable at stimuli they tolerated yesterday. Refusing tasks they’ve mastered. Three nights of poor sleep, and by the fourth morning the whole plan falls apart.

When that happens, the clinically correct response isn’t always to adjust the reinforcement schedule. Sometimes it’s to ask what’s happening in the body.

Why this is our business (and why only up to a point)

Applied behavior analysis has a precise term for this: a motivating operation of biological origin. Pain, sleep deprivation, digestive discomfort, and illness alter reinforcer value and the probability of problem behavior. They sit outside the contingencies we design, but they run through every session.

When a minimally verbal child cannot report abdominal pain, behavior may be the only signal available. This is not alternative-medicine speculation — it is exactly what the consensus panel of gastroenterologists, neurologists, and developmental pediatricians led by Timothy Buie concluded in Pediatrics in 2010 [1]. GI disorders are common in autistic individuals, they warrant the same medical attention any other child would receive, and in nonverbal children behavioral disturbance may be the only outward manifestation of distress.

Here is the boundary, stated plainly: identifying the possibility of a medical contributor is within our role. Diagnosing it, treating it, or recommending supplements or diets is not. The BACB Ethics Code for Behavior Analysts is explicit in section 2.01 on scope of competence, and standard 2.03 obligates us to refer and collaborate with other professionals when the case requires it. A BCBA recommending a supplement protocol is practicing outside their license; a BCBA who fails to document a behavior pattern consistent with possible pain and communicate it to the family and pediatrician is also not doing the job well.

The practical division. We contribute the data: latency, topography, time-of-day patterns, correlation with meals and sleep, functional assessment results. The physician contributes diagnosis and treatment. The family decides. That’s the interdisciplinary model we pursue in every case.

The actual state of the evidence in 2026

This is where honesty is required, because the autism information space is saturated with promises.

In December 2025, Nature Human Behaviour published the broadest review to date of complementary, alternative, and integrative medicine (CAIM) in autism. Corentin Gosling’s team assessed 248 meta-analyses spanning roughly 200 clinical trials and more than 10,000 participants across 19 common CAIM interventions. Their conclusion was direct: there is no high-quality evidence supporting the efficacy of any CAIM intervention for core or associated autism symptoms. Several showed promising signals, but resting on very low-quality evidence [2]. The group also published an open platform, ebiact-database.com, so families and clinicians can review the evidence intervention by intervention. We recommend it without reservation.

A parallel systematic review by Antonio Persico and colleagues in Progress in Neuro-Psychopharmacology and Biological Psychiatry reviewed 115 randomized controlled trials covering 133 compounds. Their read was somewhat more nuanced, but it should be cited precisely: the authors conclude that clinical use is fully evidence-based only for melatonin (for sleep disturbance), and that for six additional compounds — folinic acid, N-acetylcysteine, L-carnitine, coenzyme Q10, sulforaphane, and metformin — clinical use may be acceptable with caution, but more research is necessary [3].

Editorial accuracy note. We have seen this Persico review cited across several sites as though it declared those six compounds “promising and safe” for clinical use. That reading inflates the evidence level. The only intervention the review treats as fully evidence-based is melatonin. We publish this clarification because families deserve to know the difference between “there’s a signal, more research needed” and “this is established.”

What do we do with this? Two things at once. First, hold without qualification that the interventions with solid support for skill development, communication, and quality of life are behavioral and developmental: ABA, naturalistic developmental behavioral interventions, speech-language pathology, occupational therapy, educational support. Nothing discussed in this series replaces them. Second, don’t confuse “no high-quality evidence for treating autism” with “clinically unimportant.” A child’s chronic constipation does not need a randomized trial in autism to deserve pediatric treatment. It needs a pediatrician.

Five medical areas that recur in the literature

We present these as areas warranting medical evaluation when clinical signs are present — not as a causal model of autism, and not as a list of things to treat. None defines autism and none is present in every child.

1. Gastrointestinal function

A systematic review by Calliope Holingue and colleagues in Autism Research (2018) found that the prevalence of at least one GI symptom in autistic children is estimated between 23% and 70% depending on study design [4]. The range is wide precisely because this is hard to measure; the point is that it isn’t a marginal finding. We cover it in Part 2.

2. Sleep

This is the best-supported area in the entire conversation and, oddly, the least discussed in popular content. Melatonin is the only intervention the Persico review treats as fully evidence-based [3]. For an ABA team, sleep is also the highest-impact motivating operation in practice: a child who slept four hours will not acquire a new skill that day, no matter how well the program is designed.

3. Nutritional status

James Adams and colleagues published a 2011 randomized, double-blind, placebo-controlled trial of a vitamin/mineral supplement in 141 children and adults with autism, with statistically significant improvements on several parent-reported measures [5]. A companion study that year found measurably lower levels of several nutrients versus neurotypical controls [6]. That’s a real signal. It is also a single trial with caregiver-reported primary measures, and any individual child’s nutritional status is determined by lab work, not a blog post.

4. Immune regulation

Immune differences have been documented in subgroups of autistic children. The best-characterized example is folate receptor alpha autoantibodies, reviewed by Daniel Rossignol and Richard Frye in Journal of Personalized Medicine (2021) [7]. We return to this — and to what the FDA actually decided about it — in Part 3.

5. Environmental exposures

Epidemiological studies, including Janie Shelton and colleagues in Environmental Health Perspectives (2014), have associated prenatal residential proximity to agricultural pesticide application with increased neurodevelopmental disorder risk [8]. These are observational studies: they describe association, not individual causation. They’re relevant to public policy and to reasonable family choices, not to explaining any particular child’s diagnosis.

Diet: what can and cannot be said

A randomized, double-blind, placebo-controlled trial published in The Lancet in 2007 by Donna McCann and colleagues tested artificial food colors and sodium benzoate in 297 typically developing British children and found measurable increases in hyperactivity at doses found in everyday foods [9]. It was not a study in autism, and that qualifier matters. But it’s reasonable evidence that certain additives affect children’s behavior generally.

On the gluten-free, casein-free diet, the evidence is genuinely split. The ScanBrit trial by Paul Whiteley and colleagues (2010) found benefits on communication and social interaction subscores at twelve months [10]. Susan Hyman and colleagues (2016), using a double-blind challenge design, found no significant benefit on standardized measures [11]. The Gosling 2025 review places it among interventions without high-quality evidence [2].

Our position as an ABA provider: a child’s dietary decisions belong to the family together with their pediatrician or a registered dietitian nutritionist. What we can offer, and do offer, is what we do best: if your family pursues a clinically supervised dietary trial, our team can collect structured behavioral data across the trial period and the reintroduction. That turns a subjective impression into usable information. We can also target food selectivity as a behavioral goal, which is squarely within our scope.

Clinical note for BCBAs and RBTs

Three operational practices we apply on our cases:

Rule out medical contribution before escalating the behavior plan. With sudden-onset problem behavior, loss of previously mastered skills, self-injury directed at head/abdomen/ears, or behavioral disturbance with a cyclical or postprandial pattern, document the pattern and communicate it to the family with a recommendation for medical evaluation before intensifying reduction procedures. Escalating contingencies against untreated pain is both ineffective and an ethics problem.

Build motivating variables into routine data collection. Sleep hours, bowel movements, illness, new medication or dose change. An ABC record without these leaves out a meaningful share of the variance. The temporal correlation you document may be the most useful thing the pediatrician receives.

Stay in role when communicating. Describe behavior and data; don’t interpret etiology or suggest treatments. Useful framing: “We recorded self-injury directed at the abdomen in 70% of post-lunch sessions over the last three weeks, with no such pattern in morning sessions. We recommend discussing this with your pediatrician.” That satisfies BACB standard 2.03 without crossing into 2.01.

For families: what to bring to the next medical visit

If any of this resonates, the most valuable thing you can do is not to change your child’s diet tomorrow. It’s to walk into the next pediatric appointment with data. Ask your ABA team for a summary of behavioral patterns over the last four to six weeks. Log sleep and bowel movements for two weeks. Note what changed before the behavior changed.

And something we say often in our family meetings: the volume of contradictory information in this field would exhaust anyone, and feeling overwhelmed is not a sign you’re getting it wrong. The reasonable path here is slow, coordinated, and data-driven. Moving deliberately is, in fact, doing this well.

Questions about your child’s program? Our clinical team can meet with you to review your data, discuss goals, and explain how we coordinate with your pediatrician. Call (813) 655-8159 or write to contact@hopefultherapies.com. We serve families in Brandon, Lakeland and Winter Haven, Florida.

About this series. This post discusses and responds to “Beyond Behavior: A Functional Medicine Roadmap for Autism and Childhood Neurodevelopmental Conditions” by Jill Carnahan, MD, published by the Foundation for Alternative and Integrative Medicine. The text on this page is original to Hopeful Therapies. We verified the primary sources the author cites and, where our reading of the evidence differs from hers, we say so explicitly. We recommend reading the original.

References

  1. Buie T, Campbell DB, Fuchs GJ III, et al. Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics. 2010;125(Suppl 1):S1-S18. doi:10.1542/peds.2009-1878C
  2. Gosling CJ, Boisseleau L, Solmi M, et al. Complementary, alternative and integrative medicine for autism: an umbrella review and online platform. Nat Hum Behav. 2025;9(12):2610-2619. nature.com/articles/s41562-025-02256-9
  3. Persico AM, Asta L, Chehbani F, et al. The pediatric psychopharmacology of autism spectrum disorder: A systematic review — Part II: The future. Prog Neuropsychopharmacol Biol Psychiatry. 2025;136:111176. sciencedirect.com
  4. Holingue C, Newill C, Lee LC, Pasricha PJ, Fallin MD. Gastrointestinal symptoms in autism spectrum disorder: a review of the literature on ascertainment and prevalence. Autism Res. 2018;11(1):24-36. doi:10.1002/aur.1854
  5. Adams JB, Audhya T, McDonough-Means S, et al. Effect of a vitamin/mineral supplement on children and adults with autism. BMC Pediatr. 2011;11:111. doi:10.1186/1471-2431-11-111
  6. Adams JB, Audhya T, McDonough-Means S, et al. Nutritional and metabolic status of children with autism vs. neurotypical children. Nutr Metab (Lond). 2011;8(1):34. doi:10.1186/1743-7075-8-34
  7. Rossignol DA, Frye RE. Cerebral folate deficiency, folate receptor alpha autoantibodies and leucovorin (folinic acid) treatment in autism spectrum disorders: a systematic review and meta-analysis. J Pers Med. 2021;11(11):1141. PubMed 34834493
  8. Shelton JF, Geraghty EM, Tancredi DJ, et al. Neurodevelopmental disorders and prenatal residential proximity to agricultural pesticides: the CHARGE study. Environ Health Perspect. 2014;122(10):1103-1109. doi:10.1289/ehp.1307044
  9. McCann D, Barrett A, Cooper A, et al. Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in the community: a randomised, double-blinded, placebo-controlled trial. Lancet. 2007;370(9598):1560-1567. doi:10.1016/S0140-6736(07)61306-3
  10. Whiteley P, Haracopos D, Knivsberg AM, et al. The ScanBrit randomised, controlled, single-blind study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders. Nutr Neurosci. 2010;13(2):87-100. doi:10.1179/147683010X12611460763922
  11. Hyman SL, Stewart PA, Foley J, et al. The gluten-free/casein-free diet: a double-blind challenge trial in children with autism. J Autism Dev Disord. 2016;46(1):205-220. doi:10.1007/s10803-015-2564-9

Important notice. Hopeful Therapies provides applied behavior analysis (ABA) services. We are not a medical provider and do not diagnose or treat medical conditions, nor do we prescribe diets, supplements, or medications. This content is educational and does not constitute medical advice or substitute for the relationship with your pediatrician or other qualified health professional. Do not start, stop, or change any treatment, diet, or supplement based on this post. Biomedical interventions mentioned are described solely to inform the conversation between families and their medical team. Our services are delivered in accordance with the BACB Ethics Code for Behavior Analysts and applicable Florida Agency for Health Care Administration (AHCA) requirements. We have no commercial relationship with any supplement manufacturer, laboratory, or testing provider mentioned or linked in this series.

How to Choose an ABA Provider in Central Florida: 10 Questions to Ask

by

Choosing an ABA provider is one of the more consequential decisions a parent makes, and it usually has to be made quickly, under stress, with very little information. These are the things worth checking before you sign anything.

1. Who is the BCBA, and how present are they?

A Board Certified Behavior Analyst designs and supervises your child’s programme. Ask for their name, check their certification on the BACB registry, and ask specifically how many supervision hours your child will receive. A plan written by a BCBA who then disappears is a common and avoidable problem.

2. How are goals chosen?

The goals should come from your child’s assessment and your family’s priorities — not from a template. If the draft plan does not include at least one goal you specifically asked for, ask why.

3. Is caregiver training real or nominal?

Ask what caregiver training involves, how often it happens and who delivers it. Skills that only appear in the clinic are of limited use on a Saturday morning at Publix.

4. Can you see the data?

Ask how progress is shared and how often. You should be able to see graphs of your child’s goals and understand them. “He’s doing great” is not a progress report.

5. Do therapies talk to each other?

If your child also needs speech or occupational therapy, a provider offering all of them under one roof means shared goals and one conversation instead of three. It also saves a lot of driving.

6. Waitlists and honesty about them

Ask for a start date, not a place in a queue. In Central Florida, waits of several months are common, and a provider who is straight with you about timing is telling you something about how they will communicate later.

7. Location and the reality of the drive

ABA works through consistency. A clinic forty-five minutes away in Tampa traffic looks fine on a map and collapses in week three. Families in Polk County should look at options in Lakeland, Winter Haven, Bartow, Auburndale and Haines City; families in eastern Hillsborough at Brandon, Riverview and Valrico.

8. Insurance handled properly

Ask the provider to verify your benefits and give you the expected cost in writing before therapy starts, including what happens if an authorisation lapses. Surprise bills are the single most common complaint families have about ABA.

9. Red flags

  • Promises of a cure, or of “recovery” from autism
  • Pressure to sign immediately, or refusal to put costs in writing
  • Unwillingness to let you observe sessions
  • No named BCBA, or a BCBA you never meet
  • Goals aimed at suppressing harmless self-soothing behaviours
  • Dismissing your concerns about how your child reacts to therapy

10. Trust what you see in your child

Data matters, but so does the child in front of you. If your child is anxious about going, weeks into therapy, say so out loud and expect the provider to take it seriously. A good team changes course.

About Hopeful Therapies

We provide ABA, speech, occupational and physical therapy for children with autism and developmental delays at three Central Florida clinics: Brandon, Lakeland and Winter Haven. Call (813) 655-8159 or request a consultation.

Early Signs of Autism in Toddlers: What Parents Should Look For

by

If you have found yourself watching your toddler at the playground and quietly comparing him to the other children, you are not being paranoid. Parents are usually the first to notice that something is different, often months before anyone else says a word about it. Here is what those early differences tend to look like — and what to do if you recognise them.

Why noticing early matters

Autism can be reliably identified in many children by age two, and the brain is at its most adaptable in those first years. Children who start therapy early tend to make faster gains in communication, play and independence. Waiting rarely makes anything clearer; it usually just costs time.

Social and communication signs

  • Rarely responds to his own name by 12 months
  • Little or no babbling, pointing or waving by 12 months
  • No single words by 16 months, or no two-word phrases by 24 months
  • Avoids or gives very brief eye contact
  • Does not bring you things to show you, or look where you point
  • Prefers to play alone, even when other children are close by
  • Does not imitate faces, sounds or simple actions
  • Loses words or social skills he used to have — at any age

Behaviour and sensory signs

  • Lines up toys, spins wheels, or plays with parts of toys rather than the whole
  • Repeats the same phrases from videos or books out of context
  • Hand flapping, rocking, spinning or toe walking
  • Becomes very distressed by small changes to routine
  • Extreme reactions to sound, light, texture or smell — or unusually little reaction to pain
  • A very restricted diet, often by colour or texture
  • Intense, narrow interests that are hard to interrupt

One or two of these on their own do not mean much. Lots of toddlers line up cars or hate haircuts. What matters is the pattern: several signs together, across different situations, that persist over time.

What is not a sign

Being shy is not autism. Being a late talker is not automatically autism either — some children simply talk later. Autism is also not caused by screen time, by parenting style, or by anything you did or did not do. Those myths cause a great deal of unnecessary guilt.

What to do next

  1. Write it down. Note what you see, how often, and at what age. Specifics help far more than “he seems behind”.
  2. Take a short video. Children rarely perform their concerns in a ten-minute appointment. A phone clip is powerful evidence.
  3. Ask your pediatrician for a developmental screening. It is part of routine well-child visits at 18 and 24 months, but you can ask at any visit.
  4. Ask for a referral for a full evaluation if the screening raises concerns. In Florida you can also contact Early Steps for children under three.
  5. Do not wait for the diagnosis to start support. Speech and occupational therapy do not require an autism diagnosis, and skills built now are not wasted whatever the outcome.

If it turns out to be autism

A diagnosis is a description, not a verdict. It does not change who your child is; it changes what help he can access. Most families we meet describe two feelings at once: grief for the picture they had in their head, and relief that there is finally a name and a plan. Both are normal.

Talk to us

Hopeful Therapies provides ABA, speech, occupational and physical therapy for children in Brandon, Lakeland and Winter Haven. If you are worried about your child, call (813) 655-8159 or send us a message. There is no waitlist, and a first conversation costs you nothing.

This article is general information for parents and caregivers. It is not a diagnosis. Only a qualified professional can evaluate and diagnose autism spectrum disorder.